About: Introduction of a point mutation into an HLA class I single-chain trimer induces enhancement of CTL priming and antitumor immunity

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Introduction of a point mutation into an HLA class I single-chain trimer induces enhancement of CTL priming and antitumor immunity Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Introduction of a point mutation into an HLA class I single-chain trimer induces enhancement of CTL priming and antitumor immunity
Creator	Matsui, Masanori Akatsuka, Toshitaka Kawano, Masaaki Matsushita, Sho
Source	PMC
abstract	We previously discovered one particular HLA-A02:01 mutant that enhanced peptide-specific cytotoxic T lymphocyte (CTL) recognition in vitro compared to wild-type HLA-A02:01. This mutant contains a single amino acid substitution from histidine to leucine at position 74 (H74L) that is located in the peptide-binding groove. To investigate the effect of the H74L mutation on the in vivo CTL priming, we took advantage of the technology of the HLA class I single-chain trimer (SCT) in which three components involving a peptide, β2 microglobulin and the HLA class I heavy chain are joined together via flexible linkers. We generated recombinant adenovirus expressing SCT comprised influenza A matrix protein (FMP)-derived peptide, β2 microglobulin and the H74L heavy chain. HLA-A02:01 transgenic mice were immunized with the adenovirus, and the induction of peptide-specific CTLs and antitumor immunity was investigated. It was clearly shown that the H74L mutation enabled the HLA-A02:01 SCT molecule to dramatically enhance both in vivo priming of FMP-specific CTLs and protection against a lethal challenge of tumor cells expressing FMP. These data present the first evidence that a simple point mutation in the HLA class I heavy chain of SCT is beneficial for improving CTL-based immunotherapy and prophylaxis to control tumors.
has issue date	2014-07-02(xsd:dateTime)
bibo:doi	10.1038/mtm.2014.27
bibo:pmid	26015969
has license	cc-by-nc-sa
sha1sum (hex)	f762eef06ad6975bb55dc425f10e33101d378379
schema:url	https://doi.org/10.1038/mtm.2014.27
resource representing a document's title	Introduction of a point mutation into an HLA class I single-chain trimer induces enhancement of CTL priming and antitumor immunity
has PubMed Central identifier	PMC4362367
has PubMed identifier	26015969
schema:publication	Mol Ther Methods Clin Dev
resource representing a document's body	covid:f762eef06ad6975bb55dc425f10e33101d378379#body_text
is schema:about of	named entity 'HLA CLASS I' named entity 'INTRODUCTION' named entity 'HLA' named entity 'beneficial' named entity 'control' named entity 'peptide' named entity 'mutation' named entity 'vivo' named entity 'enhancement' named entity 'Matsui' named entity 'A POINT' named entity 'ENHANCEMENT' named entity 'IMMUNITY' named entity 'POINT MUTATION' named entity 'EVIDENCE' named entity 'IMMUNOTHERAPY' named entity 'IMPROVING' named entity 'TO CONTROL' named entity 'RECOGNITION' named entity 'ADENOVIRUS' named entity 'WILD-TYPE' named entity 'ENHANCED' named entity 'SINGLE' named entity 'AMINO ACID SUBSTITUTION' named entity 'PRESENT' named entity 'PRIMING' named entity 'SIMPLE' named entity 'POINT MUTATION' named entity 'LEUCINE' named entity 'PEPTIDE-BINDING' named entity 'PROPHYLAXIS' named entity 'RECOMBINANT ADENOVIRUS' named entity 'HLA CLASS I' named entity 'INVOLVING' named entity 'TUMOR CELLS' named entity 'TRIMER' named entity 'INFLUENZA A' named entity 'SINGLE' named entity 'MUTANT' named entity 'PRIMING' named entity 'CTL' named entity 'TRIMER' named entity 'ANTITUMOR' named entity 'IN VIVO' named entity 'B22' named entity 'PROTEIN ' named entity 'MUTATION' named entity 'BENEFICIAL' named entity 'PEPTIDE' named entity 'POSITION' named entity 'INDUCTION' named entity 'BASED' named entity 'EFFECT' named entity 'HLA-A' named entity 'CHAIN' named entity 'FLEXIBLE' named entity 'TECHNOLOGY' named entity 'INVESTIGATED' named entity 'SCT' named entity 'COMPONENTS' named entity 'ADVANTAGE' named entity 'IN VITRO' named entity 'HISTIDINE' named entity 'ENABLED' named entity 'IMMUNIZED' named entity 'MOLECULE' named entity 'CYTOTOXIC T LYMPHOCYTE' named entity 'COMPARED' named entity 'DATA' named entity 'TUMORS' named entity 'PROTECTION' named entity 'CHAIN' named entity 'CHALLENGE' named entity 'ENHANCE' named entity 'MICROGLOBULIN' named entity 'TRANSGENIC MICE' named entity 'CONTAINS' named entity 'LETHAL'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software